Pay in 4 interest-free payments of $5.64 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Allison Whitten AstraZeneca reports mixed Phase 3 results across oncology and rare disease AstraZeneca reported mixed late-stage clinical results, with its Claudin 18.2-targeting antibody-drug conjugate sonesitatug vedotin meeting its primary endpoint in patients with previously treated advanced gastric cancer, while rare disease therapy Ultomiris missed the primary endpoint in a Phase 3 trial for thrombotic microangiopathy following haematopoietic stem cell transplantation (HSCT-TMA)
Continue with checkout to enter your billing and shipping information to complete your transaction
Each injection is packed with essential vitamins, antioxidants, and amino acidshelping your body use the nutrients right away for fast, noticeable results
many users find cooked, milder preparations are better tolerated than raw, heavily spiced plates
US$ 20.88
US$ 21.11
US$ 28.39
US$ 24.20
US$ 24.01
US$ 21.13
